|
Exosomal drug formulations
|
1R41CA189517-01
|
$225,000
|
$225,000
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
1R01CA182284-01A1
|
$346,525
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
DNA Mismatch repair and cancer in murine models
|
5R01CA076329-17
|
$369,167
|
$121,825
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Proton-coupled folate/antifolate transport
|
2R01CA082621-16
|
$491,190
|
$491,190
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
3P30CA013330-41S1
|
$75,000
|
$10,500
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
3P30CA013330-41S2
|
$148,500
|
$20,790
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
5P30CA013330-41
|
$3,585,248
|
$501,935
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Taxol: Mechanisms of Action and Resistance
|
5R01CA077263-14
|
$390,474
|
$390,474
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Targeting PML for therapy in leukemia-initiating cells
|
5R00CA139009-05
|
$241,530
|
$79,705
|
ITO, KEISUKE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Chemical Modulation of Orphan Nuclear Receptor Function
|
3R01CA127231-05S2
|
$76,985
|
$76,985
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
5R01CA161879-03
|
$317,989
|
$317,989
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
|
5R01CA154755-04
|
$483,713
|
$483,713
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Nemours Community Clinical Oncology Program
|
3U10CA176879-01S1
|
$89,460
|
$44,730
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Development of Transporter Targeted Platinum Drugs for Pediatric Tumor
|
1R43CA183186-01
|
$190,000
|
$190,000
|
MAMELOK, RICHARD
|
APRICITY THERAPEUTICS, INC.
|
|
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors
|
2R42CA156930-02
|
$534,844
|
$534,844
|
JONES, BARRY
|
ARISAPH PHARMACEUTICALS, INC.
|
|
Bay Area Tumor Institute CCOP
|
3U10CA045461-24S1
|
$81,028
|
$38,893
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
ESTROGEN RECEPTOR TARGETED TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER
|
5K23CA160664-02
|
$142,986
|
$142,986
|
GODOY, GUILHERME
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-08
|
$2,162,000
|
$237,820
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
3R01CA164024-02S1
|
$3,941
|
$3,941
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
5R01CA164024-02
|
$322,104
|
$322,104
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Characterization and targeting BRIT1 deficiency in breast cancer
|
5R01CA155151-04
|
$314,996
|
$103,949
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
1P50CA186784-01
|
$2,162,000
|
$259,440
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S1
|
$75,000
|
$4,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S3
|
$48,834
|
$2,930
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S4
|
$149,801
|
$8,988
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-08
|
$2,746,741
|
$164,804
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
1R01CA175026-01A1
|
$405,847
|
$405,847
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
|
5R01CA148761-05
|
$471,844
|
$235,922
|
ROSEN, JEFFREY
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of SRC-1 in Breast Cancer
|
5R01CA112403-08
|
$261,640
|
$86,341
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
3R01CA166749-02S1
|
$51,202
|
$16,897
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
5R01CA166749-02
|
$309,346
|
$102,084
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment
|
5R01CA140674-05
|
$274,502
|
$274,502
|
PINNEY, KEVIN
|
BAYLOR UNIVERSITY
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-29S1
|
$86,403
|
$38,881
|
NICHOLS, CRAIG
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal
|
1R41CA189537-01
|
$219,130
|
$219,130
|
DESIR, GARY
|
BESSOR PHARMA, LLC
|
|
Complex Role of HSF1 in Breast Cancer
|
1R01CA176326-01A1
|
$346,295
|
$114,277
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Hyperpolarized NMR for Studies of Cancer Therapies Targeting the Warburg Effect
|
5R01CA169470-02
|
$350,219
|
$175,110
|
GRANT, AARON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting PML for leukemia therapy.
|
5R01CA142874-05
|
$436,776
|
$218,388
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S5
|
$110,177
|
$39,664
|
KACHNIC, LISA
|
BOSTON MEDICAL CENTER
|
|
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer
|
3R25CA153955-05S1
|
$32,724
|
$8,181
|
GOLDBERG, BENNETT
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer
|
3R25CA153955-05S2
|
$45,144
|
$11,286
|
GOLDBERG, BENNETT
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer
|
5R25CA153955-05
|
$349,702
|
$87,426
|
GOLDBERG, BENNETT
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Flexible, Conformal, Polymeric Films for Lung Resection Margins
|
5R01CA149561-04
|
$336,653
|
$336,653
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Combination Therapies for Cancer Treatment
|
5R01CA049248-24
|
$318,393
|
$318,393
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Systemic cancer treatment and subsequent cognitive decline
|
5R03CA171817-02
|
$85,724
|
$85,724
|
GRODSTEIN, FRANCINE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP1-Mediated Oncogenecity
|
5R01CA085180-13
|
$680,363
|
$340,182
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Molecular Pathogenesis of the Hamartoma Syndromes
|
5P01CA120964-08
|
$1,727,206
|
$639,066
|
KWIATKOWSKI, DAVID
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Engineering a supramolecular platinum nanoparticle for pediatric cancer
|
1R21CA186009-01
|
$215,682
|
$215,682
|
SENGUPTA, SHILADITYA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways
|
5R01CA135242-05
|
$348,498
|
$348,498
|
SENGUPTA, SHILADITYA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
|
5R00CA160350-04
|
$241,349
|
$241,349
|
SHI, JINJUN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Targeting the Tumor Matrix as Anti-Invasive and Sensitizing Strategy for Glioma
|
5R01CA152065-06
|
$269,487
|
$269,487
|
VIAPIANO, MARIANO
|
BRIGHAM AND WOMEN'S HOSPITAL
|
Total relevant funding to Chemotherapy for this search: $278,101,806
|